Effective April 15, patients may bring one visitor to an appointment.
Learn more about this and other COVID-19 related updates

Clinical Trials & Research

PH3 Atez Tira Dura Sg 3 NSCLC

GO41854: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)

Disease Types: Lung (Non Small Cell),&nbs

Available at: {clinical_trial_location backspace="7"}PH3 Atez Tira Dura Sg 3 NSCLC, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}